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Summary
Background:  The  presence  of  heart  failure  (HF)  with  preserved  ejection  fraction  (HFPEF)  is
increasingly  recognized.  However,  prognostic  factors  for  HFPEF  remain  unclear.
Methods and  results:  The  data  were  derived  from  Shinken  Database  2004—2010,  a  prospec-
tive cohort  study  (n  =  15,227).  We  examined  301  consecutive  HFPEF  patients  (New  York  Heart
Association  Class  II  or  greater)  and  tracked  them  for  an  average  3.5  years.  Cardiopulmonary
exercise  testing  (CPX),  blood  exams,  and  ultrasound  cardiogram  (UCG)  were  performed  at
the ﬁrst  medical  examination.  Acute  decompensated  HF  (ADHF)  admission  was  observed  in
19 patients  (6.3%).  CPX  showed  that  the  anaerobic  threshold  was  lower  (7.3  ±  4.8  mL/min/kg
 0.02)  and  slope  of  the  increase  in  ventilation  to  the  increase  in  CO2vs. 9.7  ±  4.3  mL/min/kg,  p  =
output  (VE-VCO2 slope)  was  higher  (40.6  ±  8.5  vs.  34.6  ±  7.9,  p  <  0.01)  in  patients  with  ADHF
admission than  those  without.  Serum  brain  natriuretic  peptide  (BNP)  tended  to  be  higher  and
left atrial  (LA)  dimension  was  signiﬁcantly  greater  (47.0  ±  15.8  mm  vs.  41.0  ±  9.9  mm,  p  =  0.01)
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in  patients  with  ADHF  admission  than  those  without.  Multivariate  analysis  showed  that  higher
VE-VCO2 slope  and  greater  LA  dimension  were  independent  determinants  of  ADHF  admission.
Conclusion:  An  aggravated  CPX  parameter  and  LA  dilatation  were  associated  with  ADHF  admission
in patients  with  symptomatic  HFPEF,  suggesting  the  prognostic  role  of  cardiopulmonary  dysfunc-
tion during  exercise  and  LA  remodeling  in  the  pathogenesis  of  decompensated  HF  development
in HFPEF.
© 2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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least-squares  linear  regression  [11]. The  ventilatory  com-
pensation  point  was  determined  using  the  following  criteria:
(1)  the  ratio  of  VE  to  VCO2 starts  to  increase  after  a  periodntroduction
eart  failure  (HF)  with  preserved  ejection  fraction  (HFPEF)
s  increasingly  recognized  and  is  becoming  a  public  health
roblem  [1].  Prevalence  of  HFPEF  seems  to  be  similar  to
hat  of  patients  with  HF  with  reduced  ejection  fraction
HFREF)  [2].  Clinical  outcomes  associated  with  HFPEF  are
oor,  although  they  are  slightly  better  than  those  with  HFREF
3].
Despite  the  various  established  therapeutic  strategies
vailable  to  ameliorate  morbidity  and  mortality  in  HFREF,
here  are  not  any  therapies  that  have  been  demonstrated
o  be  beneﬁcial  in  the  management  of  patients  with  HFPEF
et.  This  relates  in  part  to  an  incomplete  understanding  of
he  pathophysiology  underlying  HFPEF.  Risk  stratiﬁcation  of
FPEF  is  quite  difﬁcult,  and  prognostic  factors  of  clinical
utcome  of  HFPEF  remain  to  be  clariﬁed.
Cardiopulmonary  exercise  testing  (CPX)  is  an  established
valuation  modality  for  patients  with  HF.  Mountains  of  clin-
cal  evidence  revealed  the  premise  for  the  strong  level  of
upport  for  the  application  of  CPX  in  the  HF  population,
onsistently  demonstrating  the  prognostic  value  [4].  In  the
resent  study,  we  examined  symptomatic  HFPEF  patients
nd  aimed  to  clarify  the  prognostic  factors  of  HFPEF,  espe-
ially  focusing  on  cardiopulmonary  function  during  exercise.
ethods
tudy  population
he  Shinken  Database  was  established  comprising  all  the
ew  patients  visiting  the  Cardiovascular  Institute  Hospi-
al  in  Tokyo,  Japan  (‘‘Shinken’’  is  an  abbreviated  name  in
apanese  for  the  name  of  hospital),  and  excluded  patients
ith  active  cancer  and  any  foreign  travelers.  The  principle
im  of  this  hospital-based  database  is  a  surveillance  of  the
revalence  and  prognosis  of  cardiovascular  diseases  in  the
rban  areas  of  Japan.  The  registry  started  in  June  2004,
nd  thereafter  patients  have  been  continually  registered  to
he  database  annually.  The  details  of  database  were  pre-
iously  described  [5].  The  data  in  the  present  study  were
erived  from  this  database  between  June  2004  and  March
011  (Shinken  Database  2004—2010)  including  15,227  new
isiting  patients.
We  deﬁned  HFPEF  when  a  patient  has  symptomatic
eart  failure  (New  York  Heart  Association  functional  class
I  or  greater)  and  preserved  left  ventricular  (LV)  ejec-
ion  fraction  (LVEF)  (LVEF  ≥  55%).  Among  these  patients,
01  patients  who  underwent  blood  exams,  ultrasound
o
d
p
sardiogram  (UCG),  and  CPX  at  their  ﬁrst  medical  examina-
ion  were  retrospectively  examined  in  this  study.  We  tracked
hem  for  3.4  ±  1.6  years  on  average.  The  ethical  committee
t  the  Cardiovascular  Institute  granted  ethical  permission
or  this  study  and  all  the  patients  gave  written  informed
onsent.
PX
ymptom-limited  CPX  was  performed  in  all  subjects,
sing  an  upright  electromagnetically  braked  cycle  ergome-
er  (Rehcor,  Lode,  Groningen,  The  Netherlands).  Exercise
egan  with  a  4-min  warm-up  at  0  W  or  20  W  at  60  rpm,
nd  the  load  was  then  increased  incrementally  by  1  W
very  6  s  (10  W/min).  The  electrocardiogram  was  monitored
ontinuously  during  the  exercise  tests  using  a System  ML-
000  (Fukuda  Denshi  Co  Ltd.,  Tokyo,  Japan).  Cuff  blood
ressure  was  measured  at  rest  on  the  cycle  ergome-
er  and  then  every  minute  during  exercise  testing  with
n  automatic  indirect  manometer  (FB-300;  Fukuda  Denshi
o  Ltd.).
Through  a  rubber  mask  attached  to  the  subject’s  face,
reath-by-breath  O2 uptake  (VO2),  CO2 output  (VCO2),  and
entilation  (VE)  were  measured  during  the  test  using  an
E-300S  Respiromonitor  (Minato  Medical  Science,  Osaka,
apan),  as  previously  described  [6,7]. The  system  was  care-
ully  calibrated  before  each  study.  Prior  to  any  calculation
f  the  parameters  from  the  respiratory  gas  analysis,  breath-
y-breath  data  were  interpolated  to  give  second-by-second
alues,  after  which  they  were  calculated  as  successive  3-s
verages.  Then,  a  ﬁve-point  moving  average  of  these  data
as  performed.
The  respiratory  variables  at  peak  exercise  were  deﬁned
s  the  average  values  obtained  during  the  last  15  s of
ncremental  exercise.  The  anaerobic  threshold  (AT)  was
etermined  by  the  V-slope  analysis  [8—10]. The  ratio  of  the
ncrease  in  VO2 to  the  increase  in  work  rate  (VO2/WR)
as  calculated  by  a  least-squares  linear  regression  from  the
ata  recorded  between  30  s  after  the  start  of  incremen-
al  exercise  to  30  s  before  the  end  of  the  exercise  [11].
he  slope  of  the  increase  in  VE  to  the  increase  in  VCO2
VE-VCO2 slope)  was  calculated  from  the  start  of  incremen-
al  exercise  to  the  ventilatory  compensation  point  by  thef  decrease  or  stasis;  and  (2)  the  end-tidal  PCO2 starts  to
ecrease  after  a  period  of  stasis.  When  the  ventilatory  com-
ensation  point  could  not  be  clearly  identiﬁed,  the  VE-VCO2
lope  was  calculated  from  the  data  recorded  between  the
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start  of  incremental  exercise  and  the  end  of  the  exercise
[11].
Patient  follow-up
The  follow-up  data  were  obtained  from  the  database  by
being  linked  to  the  medical  records  of  the  hospital  and  by
study  documents  of  prognosis  sent  once  a  year  to  those
who  stopped  hospital  visits  or  who  were  referred  to  other
hospitals.  Admission  for  acute  decompensated  HF  (ADHF)
was  the  primary  endpoint  of  the  present  study.  Admis-
sion  for  ADHF  was  deﬁned  as  exacerbation  of  chronic  HF
which  required  hospitalization  and  was  determined  by  the
physician’s  decision  in  an  outpatient  clinic  according  to  the
symptoms,  physical  examinations,  laboratory  data,  chest
X-rays,  etc.
Statistical  analysis
In  the  patients’  background,  the  categorical  and  consecu-
tive  data  are  presented  as  number  (%)  and  mean  ±  standard
deviation,  respectively.  The  chi-square  test  was  used  for
the  group  comparison,  and  the  unpaired  t-test  was  used
for  the  comparison  of  the  consecutive  variables  between
2  groups  (patients  with  ADHF  and  those  without  it).  Uni-
variate  Cox  regression  analysis  was  used  to  identify  the
co-factors  with  signiﬁcant  effects  on  admission  of  ADHF.
Stepwise  multivariate  Cox  regression  analysis  was  per-
formed  to  determine  the  independent  prognostic  factors
for  ADHF  admission.  These  analyses  were  performed  using
SPSS  (SPSS  Inc.,  Chicago,  IL,  USA)  for  Windows  (Microsoft
Corp.,  Redmond,  WA,  USA),  version  14.0  software.  Sta-
tistical  signiﬁcance  was  set  at  two-sided  p-value  of
<0.05.
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Table  1  Patients’  background  characteristics.
Admission  for  ADHF  
Absent  (n  =  282)  
Age  (years)  64.0  ±  11.2  
Male gender  (%)  174  (62)  
BMI (kg/m2)  22.9  ±  3.7  
UA (mg/dL)  5.9  ±  1.5  
BNP (pg/mL)  208  ±  314  
Hemoglobin  (g/dL)  13.2  ±  1.7  
Hypertension  (%)  159  (56)  
Dyslipidemia  (%)  142  (50)  
Diabetes mellitus  (%)  87  (31)  
Beta-blockers  (%)  176  (62)  
ACE-Is (%)  66  (23)  
ARBs (%)  130  (46)  
CCBs (%)  76  (27)  
Statins (%) 108  (38)  
Diuretics (%) 178  (63)
ADHF, acute decompensated heart failure; BMI, body-mass index; UA, ur
enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium 
expressed as mean ± standard deviation, or counts (percentage).361
esults
haracteristics  of  the  study  patients
DHF  admission  was  observed  in  19  patients,  i.e.  6.3%  of
he  study  population  (Table  1).  There  were  no  signiﬁcant
ifferences  between  the  patients  with  ADHF  and  those  with-
ut  it  in  sex,  body-mass  index,  serum  hemoglobin  level,
revalence  of  hypertension,  dyslipidemia,  and  diabetes  mel-
itus.  Patients  with  ADHF  admission  tended  to  be  older
han  those  without  (68.3  ±  14.0  years  vs.  64.0  ±  11.2  years,
 =  0.113).  Serum  brain  natriuretic  peptide  (BNP)  levels
lso  tended  to  be  higher  in  patients  with  ADHF  admission
han  those  without  (329  ±  254  pg/mL  vs.  208  ±  314  pg/mL,
 =  0.120).  Prevalence  of  medications  including  beta-
lockers,  angiotensin-converting  enzyme  inhibitors  (ACE-I),
ngiotensin  II  receptor  blockers  (ARB),  calcium  channel
lockers  (CCB),  statins,  and  diuretics  were  comparable
etween  the  two  groups  (Table  1).
PX  parameter
T  was  signiﬁcantly  lower  (7.3  ±  4.8  mL/min/kg  vs.
.7  ±  4.3  mL/min/kg,  p  =  0.023)  and  VE-VCO2 slope  was
igniﬁcantly  higher  (40.6  ±  8.5  vs.  34.6  ±  7.9,  p  =  0.002)
n  patients  with  ADHF  admission  than  those  without
Table  2).  Peak  VO2 tended  to  be  lower  in  patients  with
DHF  admission  than  those  without  (13.2  ±  4.3  mL/min/kg
s.  15.2  ±  4.9  mL/min/kg,  p  =  0.096).  VO2/WR  was
omparable  between  the  two  groups.  Resting  systolic
lood  pressure  (SBP),  diastolic  blood  pressure  (DBP),  and
eart  rate  (HR)  and  SBP  were  comparable  between  the
wo  groups.  SBP,  DBP,  and  HR  at  peak  exercise  were  also
omparable  between  the  two  groups.
p-value
Present  (n  =  19)
68.3  ±  14.0  N.S.
12  (63)  N.S.
23.2  ±  4.6  N.S.
6.1  ±  1.9  N.S.
329  ±  254  N.S.
13.4  ±  1.8  N.S.
11  (58)  N.S.
9  (47)  N.S.
5  (26)  N.S.
11  (58)  N.S.
5  (26)  N.S.
10  (53)  N.S.
7  (37)  N.S.
7  (37)  N.S.
16  (84)  N.S.
ic acid; BNP, brain natriuretic acid; ACE-I, angiotensin-converting
channel blocker; Statin, HMG-CoA reductase inhibitor. Data are
362  H.  Kaneko  et  al.
Table  2  CPX  parameters.
Admission  for  ADHF  p-value
Absent  (n  =  282)  Present  (n  =  19)
AT  (mL/min/kg) 9.7  ±  4.3  7.3  ±  4.8  0.023
PeakVO2 (mL/min/kg)  15.2  ±  4.9  13.2  ±  4.3  N.S.
VE-VCO2 slope  34.6  ±  7.9  40.6  ±  8.5  0.002
VO2WR  (mL/min/W)  8.5  ±  2.1 7.9  ±  2.8 N.S.
Rest HR  (bpm) 79  ±  14 77  ±  17 N.S.
Rest SBP  (mmHg) 121  ±  21 113  ±  20 N.S.
Rest DBP  (mmHg) 70  ±  13 64  ±  11 N.S.
Peak HR  (bpm)  119  ±  28  119  ±  33  N.S.
Peak SBP  (mmHg)  168  ±  35  153  ±  30  N.S.
Peak DBP  (mmHg)  79  ±  16  75  ±  18  N.S.
ADHF, acute decompensated heart failure; AT, anaerobic threshold; PeakVO2, peak O2 uptake; VE-VCO2 slope, slope of the increase in
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chocardiogram  ﬁndings
n  patients  with  HFPEF,  LV  end-diastolic  and  end-systolic
imensions,  LV  fractional  shortening,  LVEF,  interventricular
eptum  thickness,  and  posterior  wall  thickening  were  com-
arable  between  patients  with  ADHF  admission  and  those
ithout  (Table  3).  Left  atrial  dimension  (LAD)  was  signiﬁ-
antly  greater  in  patients  with  ADHF  admission  than  those
ithout  (47.0  ±  15.8  mm  vs.  41.0  ±  9.9  mm,  p  =  0.014).
ultivariate  Cox  regression  analysis
nivariate  Cox  regression  analysis  showed  that  age,  use  of
iuretics,  AT,  VE-VCO2 slope,  VO2/WR,  DBP,  at  rest  and
AD  were  signiﬁcant  prognostic  factors  for  ADHF  admission
n  HFPEF  (Table  4).  Stepwise  multivariate  Cox  regression
nalysis  including  the  signiﬁcant  predictors  in  the  univariate
odel  showed  that  higher  VE-VCO2 slope  and  greater  LAD
ere  the  independent  prognostic  factors  for  ADHF  admission
n  the  particular  subjects  (Table  5).
iscussion
his  study  showed  that  higher  VE-VCO2 slope  and  LA  dilata-
ion  were  independently  associated  with  the  development  of
DHF  in  HFPEF.  The  ﬁndings  might  suggest  that  cardiopul-
onary  dysfunction  during  exercise  and  LA  remodeling
ontributed  to  the  pathogenesis  of  ADHF  development  in
FPEF.
Growing  clinical  evidence  revealed  that  about  half  of
atients  with  the  chronic  congestive  HF  have  preserved  LVEF
12]  and  the  prevalence  of  HFPEF  is  thought  to  be  increasing
13].  Despite  the  increased  prevalence  of  HFPEF,  prognos-
ic  factors  of  HFPEF  remain  unclear.  Mountains  of  clinical
vidence  revealed  that  plasma  BNP  is  elevated  in  HF  [14]
nd  is  a  strong  predictor  of  clinical  outcomes  in  chronic  HF
15].  BNP  is  also  increased  in  HFPEF  patients,  independent
f  the  presence  of  LV  hypertrophy  [16], which  is  compati-
le  with  results  of  other  clinical  studies  [17]. However,  BNP
s  known  to  be  increased  in  healthy  aged  people,  females
M
o
w
trease in VO2 to the increase in work rate; HR, heart rate; SBP,
ed as mean ± standard deviation, or counts (percentage).
18], patients  with  renal  dysfunction  [19], and  patients  with
trial  ﬁbrillation  [20], which  are  also  clinical  characteristics
f  HFPEF.  Although  the  present  study  showed  that  serum
NP  level  tended  to  be  higher  in  patients  with  ADHF  admis-
ion  than  those  without  ADHF  admission  in  HFPEF,  to  predict
linical  outcomes  of  HFPEF  by  using  only  BNP  was  not  appro-
riate.
In  this  study,  we  aimed  to  ﬁnd  prognostic  factors  of
FPEF,  considering  pathological  features  of  HFPEF.  Altered
xtracellular  matrix  structure,  LV  ﬁbrosis,  and  increased  LV
tiffness  might  have  important  roles  in  the  development  of
FPEF.  Myocyte  growth  is  usually  associated  with  increased
onnective  tissue  and  extracellular  matrix  which  is  pre-
ominantly  composed  of  collagen  and  a  reduced  degree
f  elastin,  laminin,  and  ﬁbronectin.  Myocardial  stiffness  is
elated  to  the  composition  and  turnover  of  the  extracellu-
ar  matrix  [21]. Experimental  evidence  indicated  that  the
rogression  to  overt  HFPEF  is  associated  with  progression
f  myocardial  stiffness  rather  than  LV  relaxation  abnormal-
ties  [22]. Therefore,  LV  myocardial  stiffness  appeared  to
ave  an  important  role  in  HFPEF.  Myocardial  aging  is  char-
cterized  by  LV  ﬁbrosis  caused  by  progressive  reduction
n  cardiomyocyte  number,  increased  cardiac  ﬁbroblast  pro-
iferation,  and  LV  collagen  deposition  [23,24]. Along  with
hese  data,  patients  with  ADHF  admission  tended  to  be  older
han  patients  without  ADHF  admission  in  the  present  study.
ging  might  aggravate  HFPEF  through  accelerating  myocar-
ial  ﬁbrosis  and  result  in  development  of  ADHF.
The  prognostic  value  of  CPX  in  HFREF  is  strongly  sup-
orted  by  various  clinical  evidence  [25—27]. Peak  VO2 and
E-VCO2 slope  are  the  most  thoroughly  investigated  indices
nd  are  therefore  afforded  a  high  degree  of  clinical  recogni-
ion  and  acceptance.  This  is  particularly  true  for  peak  VO2,
lthough  several  reports  now  support  the  prognostic  superi-
rity  of  the  VE-VCO2 slope  in  patients  with  HF  [28]. Guazzi
t  al.  previously  reported  that  peak  VO2 and  VE-VCO2 slope
ere  signiﬁcant  predictors  in  both  systolic  and  diastolic  HF.
ultivariate  analysis  documented  a  similar  prognostic  value
f  peak  VO2 and  VE-VCO2 slope  in  all  systolic  HF  groups,
hereas  VE-VCO2 slope  outnumbered  peak  VO2,  suggesting
he  possible  prognostic  role  of  VE-VCO2 slope  in  HFPEF
CPX,  LA  remodeling,  and  HFPEF  –  Publish  the  unpublishable  363
Table  3  Ultrasound  cardiogram.
Admission  for  ADHF  p-value
Absent  (n  =  282)  Present  (n  =  19)
LVDd  (mm) 48.4  ±  7.4  51.4  ±  10.1  N.S.
LVDs (mm)  29.9  ±  6.2  32.5  ±  8.0  N.S.
FS (%)  38.5  ±  5.9  37.0  ±  6.5  N.S.
LVEF (%) 68.2  ±  7.3 66.1  ±  8.5 N.S.
LAD (mm) 41.0  ±  9.9 47.0  ±  15.8 0.014
IVST (mm) 9.9  ±  2.4 10.0  ±  2.2 N.S.
PWT (mm) 9.0  ±  1.7 9.1  ±  2.0 N.S.
ADHF, acute decompensated heart failure; LVDd, left ventricular end-diastolic dimension; LVDs, left ventricular end-systolic dimension;
FS, fractional shortening; LVEF, left ventricular ejection fraction; LAD, left atrial dimension; IVST, interventricular septum thickness;
PWT, posterior left ventricular wall thickness. Data are expressed as mean ± standard deviation, or counts (percentage).
Table  4  Predictors  for  ADHF  admission.
2 p-value  Hazard  ratio  95%  C.I.
Age  4.969  0.026  1.056  1.007—1.108
Male gender  0.045  0.833  0.904  0.355—2.301
BMI 0.068  0.795  1.019  0.884—1.175
UA 0.466  0.494  1.116  0.815—1.529
BNP 3.499  0.069  1.001  1.000—1.002
Hemoglobin  0.018  0.892  0.979  0.722—1.327
Hypertension  0.345  0.558  1.316  0.525—3.298
Dyslipidemia  0.000  0.998  0.999  0.404—2.468
Diabetes mellitus  0.449  0.505  0.706  0.253—1.966
Beta-blocker  0.013  0.911  0.949  0.380—2.371
ACE-Is 0.070  0.792  1.149  0.410—3.216
ARBs 0.710  0.402  1.474  0.595—3.653
CCBs 1.351  0.251  1.732  0.678—4.423
Statins 0.029  0.864  0.922  0.261—2.352
Diuretics 5.778  0.026  4.145  1.187—14.474
AT 5.995 0.017  0.899  0.823—0.981
Peak VO2 3.008  0.083  0.912  0.822—1.012
VE-VCO2 slope  9.486  0.003  1.068  1.022—1.115
VO2WR  3.707  0.048  0.827  0.685—0.998
Rest HR 0.495  0.481  0.989  0.958—1.021
Rest SBP 2.906  0.088  0.978  0.953—1.003
Rest DBP  4.658  0.031  0.955  0.916—0.996
Peak HR  0.054  0.816  0.998  0.982—1.012
Peak SBP  3.490  0.064  0.986  0.971—1.001
Peak DBP  2.331  0.129  0.975  0.944—1.007
LVDd 1.631  0.205  1.037  0.981—1.096
LVDs 2.346  0.128  1.054  0.985—1.129
FS 1.288  0.258  0.955  0.883—1.034
LVEF 1.500  0.233  0.962  0.905—1.024
LAD 6.886  0.009  1.053  1.013—1.094
IVST 0.044  0.835  1.021  0.842—1.238
PWT 0.026  0.871  0.978  0.746—1.282
All variables were entered in to a Cox proportional hazards model as continuous variables. ADHF, acute decompensated heart failure; BMI,
body-mass index; UA, uric acid; BNP, brain natriuretic acid; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
blocker; CCB, calcium channel blocker; Statin, HMG-CoA reductase inhibitor; AT, anaerobic threshold; PeakVO2, peak O2 uptake; VE-VCO2
slope, slope of the increase in ventilation to the increase in CO2 output; VO2WR, ratio of the increase in VO2 to the increase in work
rate; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVDd, left ventricular end-diastolic dimension; LVDs, left
ventricular end-systolic dimension; FS, fractional shortening; LVEF, left ventricular ejection fraction; LAD, left atrial dimension; IVST,
interventricular septum thickness; PWT, posterior left ventricular wall thickness; CI, conﬁdence interval.
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Table  5  Determinants  for  ADHF  admission.
Univariate  p-value  Exp  95%  CI  p-value
VE-VCO2 slope  0.003  1.060  1.013—1.108  0.011
LAD 0.009  1.042  1.004—1.083  0.032
ADHF, acute decompensated heart failure; VE-VCO2 slope, slope of the increase in ventilation to the increase in CO2 output; LAD, left
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[11] Koike A, Itoh H, Kato M, Sawada H, Aizawa T, Fu LT, Watanabe H.
Prognostic power of ventilatory responses during submaxi-atrial dimension; CI, conﬁdence interval.
29]. Based  on  these  clinical  reports,  we  hypothesized
hat  assessing  exercise  capacity  by  using  CPX  might  be  an
ttractive  prognostic  modality  not  only  in  HFREF  but  also
n  HFPEF.
A  subsequent  study  by  Westermann  et  al.  [30]  involv-
ng  pressure—volume  loop  analysis  found  that  enhanced  LV
tiffness  resulted  in  increased  end-diastolic  pressure  dur-
ng  exercise  and  increased  heart  rate.  Considering  the  close
elation  between  increased  end-diastolic  pressure  and  LA
verload,  LV  stiffness  which  was  an  important  pathological
eature  of  HFPEF  was  thought  to  increase  LA  overload  dur-
ng  exercise  through  increasing  LV  end-diastolic  pressure.  In
he  present  study,  greater  LAD  was  strongly  associated  with
oor  clinical  outcomes  in  HFPEF,  suggesting  that  increased
A  overload  due  to  LV  stiffness  might  have  pathological  sig-
iﬁcance  in  HFPEF.
Recently,  Maeder  et  al.  [31]  found  that  HFPEF  patients
ad  a  sharp  increase  in  pulmonary  capillary  wedge  pres-
ure  (PCWP)  at  low  work  rate,  resulting  in  early  cessation  of
xercise  when  compared  with  controls.  In  the  present  study,
e  found  that  VE-VCO2 slope,  a  marker  of  cardiopulmonary
ysfunction  reﬂecting  ventilation—perfusion  mismatch  dur-
ng  exertion,  was  more  deteriorated  in  HFPEF  with  ADHF
ompared  with  in  HFPEF  without  ADHF.  Higher  VE-VCO2
lope  in  HFPEF  patients  with  ADHF  was  probably  attributed
o  more  pronounced  ventilation—perfusion  mismatch  (long-
erm  decreased  pulmonary  blood  ﬂow  in  spite  of  preserved
entilation)  which  resulted  from  myocardial  stiffness  and
ubsequently  from  high  PCWP.  Probably  by  these  mecha-
isms,  high  VE-VCO2 slope  was  found  as  an  independent
rognostic  determinant  of  ADHF  in  the  present  study.
We  recognized  that  the  present  study  had  some  limi-
ations.  First,  because  the  sample  size  was  limited,  the
tatistical  power  might  not  be  strong  enough  for  any  neg-
tive  data  to  be  conclusive.  To  conﬁrm  the  prognostic
igniﬁcance  of  cardiopulmonary  dysfunction  during  exercise
n  the  development  of  ADHF,  a  large  prospective  clinical
rial  will  be  needed.  Second,  CPX  parameters,  UCG  ﬁnd-
ngs,  and  patients’  medical  treatment  were  not  followed  in
he  present  study.  Follow-up  data  will  be  required  to  estab-
ish  the  clinical  value  of  CPX  on  HFPEF.  Third,  this  study
as  a  retrospective  study  and  we  had  limited  data  of  UCGs
n  patients  included  in  the  present  study.  Because  HFPEF  is
hought  to  be  closely  associated  with  diastolic  dysfunction,
urther  study  which  included  more  detailed  data  about  dia-
tolic  dysfunction  such  as  E/A,  E′,  E/E′,  diastolic  perfusion
ime,  etc.  is  needed.
In  conclusion,  cardiopulmonary  dysfunction  during  exer-
ise  and  LA  remodeling  was  associated  with  worse  clinical
utcomes  in  HFPEF.  These  factors  might  have  prognostic
otential  and  pathological  signiﬁcant  in  HFPEF.cknowledgments
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